Janssen’s ulcerative colitis treatment, Stelara (ustekinumab subcutaneous) has shown positive results as maintenance therapy in phase 3 trials.
The study found that 44% of patients with severe to moderate ulcerative colitis who took 90mg of Stelara every eight weeks and 38% of those who took 90mg every 12 weeks achieved clinical remission as defined by the Mayo score, at week 44 compared to 24 percent of patients who received placebo.
